Molecular regulation of prostate cancer by Galectin-3 and estrogen receptor
Prostate cancer remains the most prevalent cancer among men worldwide. This cancer is hormone-dependent; therefore, androgen, estrogen, and their receptors play an important role in development and progression of this disease, and in emergence of the castration-resistant prostate cancer (CRPC). Gale...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-03-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2023.1124111/full |
| _version_ | 1827999682936176640 |
|---|---|
| author | Deborah Simão Souza Carla Macheroni Gustavo José Silva Pereira Carolina Meloni Vicente Catarina Segreti Porto |
| author_facet | Deborah Simão Souza Carla Macheroni Gustavo José Silva Pereira Carolina Meloni Vicente Catarina Segreti Porto |
| author_sort | Deborah Simão Souza |
| collection | DOAJ |
| description | Prostate cancer remains the most prevalent cancer among men worldwide. This cancer is hormone-dependent; therefore, androgen, estrogen, and their receptors play an important role in development and progression of this disease, and in emergence of the castration-resistant prostate cancer (CRPC). Galectins are a family of β-galactoside-binding proteins which are frequently altered (upregulated or downregulated) in a wide range of tumors, participating in different stages of tumor development and progression, but the molecular mechanisms which regulate its expression are still poorly understood. This review provides an overview of the current and emerging knowledge on Galectin-3 in cancer biology with focus on prostate cancer and the interplay with estrogen receptor (ER) signaling pathways, present in androgen-independent prostate cancer cells. We suggest a molecular mechanism where ER, Galectin-3 and β-catenin can modulate nuclear transcriptional events, such as, proliferation, migration, invasion, and anchorage-independent growth of androgen-independent prostate cancer cells. Despite a number of achievements in targeted therapy for prostate cancer, CRPC may eventually develop, therefore new effective drug targets need urgently to be found. Further understanding of the role of Galectin-3 and ER in prostate cancer will enhance our understanding of the molecular mechanisms of prostate cancer development and the future treatment of this disease. |
| first_indexed | 2024-04-10T06:02:22Z |
| format | Article |
| id | doaj.art-18d09e88ca574b9f86272802040d4721 |
| institution | Directory Open Access Journal |
| issn | 1664-2392 |
| language | English |
| last_indexed | 2024-04-10T06:02:22Z |
| publishDate | 2023-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Endocrinology |
| spelling | doaj.art-18d09e88ca574b9f86272802040d47212023-03-03T06:25:59ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922023-03-011410.3389/fendo.2023.11241111124111Molecular regulation of prostate cancer by Galectin-3 and estrogen receptorDeborah Simão SouzaCarla MacheroniGustavo José Silva PereiraCarolina Meloni VicenteCatarina Segreti PortoProstate cancer remains the most prevalent cancer among men worldwide. This cancer is hormone-dependent; therefore, androgen, estrogen, and their receptors play an important role in development and progression of this disease, and in emergence of the castration-resistant prostate cancer (CRPC). Galectins are a family of β-galactoside-binding proteins which are frequently altered (upregulated or downregulated) in a wide range of tumors, participating in different stages of tumor development and progression, but the molecular mechanisms which regulate its expression are still poorly understood. This review provides an overview of the current and emerging knowledge on Galectin-3 in cancer biology with focus on prostate cancer and the interplay with estrogen receptor (ER) signaling pathways, present in androgen-independent prostate cancer cells. We suggest a molecular mechanism where ER, Galectin-3 and β-catenin can modulate nuclear transcriptional events, such as, proliferation, migration, invasion, and anchorage-independent growth of androgen-independent prostate cancer cells. Despite a number of achievements in targeted therapy for prostate cancer, CRPC may eventually develop, therefore new effective drug targets need urgently to be found. Further understanding of the role of Galectin-3 and ER in prostate cancer will enhance our understanding of the molecular mechanisms of prostate cancer development and the future treatment of this disease.https://www.frontiersin.org/articles/10.3389/fendo.2023.1124111/fullGalectin-3β-cateninERαERβprostate cancer cells |
| spellingShingle | Deborah Simão Souza Carla Macheroni Gustavo José Silva Pereira Carolina Meloni Vicente Catarina Segreti Porto Molecular regulation of prostate cancer by Galectin-3 and estrogen receptor Frontiers in Endocrinology Galectin-3 β-catenin ERα ERβ prostate cancer cells |
| title | Molecular regulation of prostate cancer by Galectin-3 and estrogen receptor |
| title_full | Molecular regulation of prostate cancer by Galectin-3 and estrogen receptor |
| title_fullStr | Molecular regulation of prostate cancer by Galectin-3 and estrogen receptor |
| title_full_unstemmed | Molecular regulation of prostate cancer by Galectin-3 and estrogen receptor |
| title_short | Molecular regulation of prostate cancer by Galectin-3 and estrogen receptor |
| title_sort | molecular regulation of prostate cancer by galectin 3 and estrogen receptor |
| topic | Galectin-3 β-catenin ERα ERβ prostate cancer cells |
| url | https://www.frontiersin.org/articles/10.3389/fendo.2023.1124111/full |
| work_keys_str_mv | AT deborahsimaosouza molecularregulationofprostatecancerbygalectin3andestrogenreceptor AT carlamacheroni molecularregulationofprostatecancerbygalectin3andestrogenreceptor AT gustavojosesilvapereira molecularregulationofprostatecancerbygalectin3andestrogenreceptor AT carolinamelonivicente molecularregulationofprostatecancerbygalectin3andestrogenreceptor AT catarinasegretiporto molecularregulationofprostatecancerbygalectin3andestrogenreceptor |